J
John A. Barrett
Researcher at DuPont
Publications - 33
Citations - 2027
John A. Barrett is an academic researcher from DuPont. The author has contributed to research in topics: Tricine & Vitronectin. The author has an hindex of 22, co-authored 33 publications receiving 1905 citations. Previous affiliations of John A. Barrett include Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Shawn Hillier,Kevin P. Maresca,Frank J. Femia,John C. Marquis,Catherine A. Foss,Nghi Nguyen,Craig Zimmerman,John A. Barrett,William C. Eckelman,Martin G. Pomper,John Joyal,John W. Babich +11 more
TL;DR: Specific binding to PSMA in vivo was shown by competition with PMPA in LNCaP xenografts, and the absence of uptake in PC3 xenografteds.
Journal ArticleDOI
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
Kevin P. Maresca,Shawn Hillier,Frank J. Femia,D. Keith,C. Barone,John Joyal,Craig Zimmerman,Alan P. Kozikowski,John A. Barrett,William C. Eckelman,John W. Babich +10 more
TL;DR: Two lead iodine compounds were radiolabeled with (123)I and (131)Iand demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.
Journal ArticleDOI
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
John A. Barrett,R. Edward Coleman,Stanley J. Goldsmith,Shankar Vallabhajosula,Neil A. Petry,Steve Y. Cho,Thomas Armor,James B. Stubbs,Kevin P. Maresca,Michael G. Stabin,John Joyal,William C. Eckelman,John W. Babich +12 more
TL;DR: These novel radiolabeled small molecules have excellent pharmacokinetic and pharmacodynamic profiles and warrant further development as diagnostic and potentially when labeled with 131I therapeutic radiopharmaceuticals.
Journal ArticleDOI
99mTc labeling of highly potent small peptides.
Journal ArticleDOI
Labeling a Hydrazino Nicotinamide-Modified Cyclic IIb/IIIa Receptor Antagonist with 99mTc Using Aminocarboxylates as Coligands
Shuang Liu,D. Scott Edwards,Richard J. Looby,Anthony R. Harris,Michael J. Poirier,John A. Barrett,and Stuart J. Heminway,Timothy R. Carroll +7 more
TL;DR: A series of 99mTc complexes containing a hydrazinonicotinamide-conjugated cyclic IIb/IIIa receptor antagonist, cyclo, were synthesized in high yield using tricine or other aminocarboxylates as coligands and have the potential to be used as thrombus imaging agents.